...
首页> 外文期刊>Modern rheumatology >Rheumatoid arthritis complicated with myeloperoxidase antineutrophil cytoplasmic antibody (MPO-ANCA)-associated vasculitis: a case report
【24h】

Rheumatoid arthritis complicated with myeloperoxidase antineutrophil cytoplasmic antibody (MPO-ANCA)-associated vasculitis: a case report

机译:类风湿关节炎并发髓过氧化物酶抗中性粒细胞胞浆抗体(MPO-ANCA)相关血管炎:一例报告

获取原文
获取原文并翻译 | 示例
           

摘要

This article describes a patient with rheumatoid arthritis (RA) with crescentic glomerulonephritis (CrGN) associated with myeloperoxidase-antineutrophil cytoplasmic antibodies (MPO-ANCA), who responded well to methotrexate (MTX). A 48-year-old woman with a 4-year historv oi' RA was admitted with fever and elevated C-reactive protein. On laboratory evaluation, her level of MPO-ANCA was 422 EU. and urinalysis revealed pro-teinuria and hematuria. Because she was also suffering from episcleritis. vasculitis was considered. A renal biopsy was performed, which revealed necrotizing CrGN. We diagnosed RA complicated with MPO-ANCA-associated vasculitis. We considered treatment with high-dose oral prednisolone for vasculilis. but the patient refused this treatment. We started MTX at a dose of Hmg/week for RA from the time of admission, and the patient responded immediately. Biochemical parameters, including C-reactive protein, erythrocyte sedimentation rate, rheumatoid factor, and MPO-ANCA, improved. Seven months later. MPO-ANCA had decreased to 46 EU. In clinical studies, few patients have been reported with RA complicated with ANCA-associated CrGN. This case differs from previous cases in the treatment given. No high-dose steroid with intensive immunosuppres-sion or plasma exchange was required.
机译:本文介绍了患有类风湿性关节炎(RA)并伴有髓过氧化物酶-抗中性粒细胞胞浆抗体(MPO-ANCA)的新月形肾小球肾炎(CrGN)的患者,该患者对甲氨蝶呤(MTX)的反应良好。一名48岁RA病史为48岁的女性因发烧和C反应蛋白升高而入院。经实验室评估,她的MPO-ANCA水平为422欧盟。尿液分析显示前蛋白尿和血尿。因为她还患有巩膜炎。考虑血管炎。进行肾脏活检,发现坏死了CrGN。我们诊断为RA并发MPO-ANCA相关性血管炎。我们考虑用大剂量口服泼尼松龙治疗血管炎。但是病人拒绝了这种治疗。从入院开始,我们以每周Hmg / mg的剂量开始MTX治疗RA,患者立即反应。生化参数,包括C反应蛋白,红细胞沉降率,类风湿因子和MPO-ANCA,得到了改善。七个月后。 MPO-ANCA已降至46欧盟。在临床研究中,很少有人报告RA并发ANCA相关的CrGN。该病例与先前的病例不同。不需要大剂量的类固醇具有强烈的免疫抑制或血浆置换。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号